These highlights do not include all the information needed to use TYVASO safely and effectively. See full prescribing information for TYVASO.
Tyvaso ® (treprostinil) inhalation solution, for oral inhalation only
Initial U.S. Approval: 2002
INDICATIONS AND USAGE
Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). (1)
DOSAGE AND ADMINISTRATION
-
Use only with the Tyvaso Inhalation System. (2.1)
-
Administer undiluted, as supplied. A single breath of Tyvaso delivers approximately 6 mcg of treprostinil. (2.1)
-
Administer in 4 separate treatment sessions each day approximately four hours apart, during waking hours. (2.1)
-
Initial dosage: 3 breaths [18 mcg] per treatment session. If 3 breaths are not tolerated, re
